Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Change in Account Payables: 2014-2024

Historic Change in Account Payables for Axsome Therapeutics (AXSM) over the last 11 years, with Dec 2024 value amounting to $31.3 million.

  • Axsome Therapeutics' Change in Account Payables fell 1383.93% to -$37.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.0 million, marking a year-over-year decrease of 128.52%. This contributed to the annual value of $31.3 million for FY2024, which is 1410.03% up from last year.
  • As of FY2024, Axsome Therapeutics' Change in Account Payables stood at $31.3 million, which was up 1,410.03% from $2.1 million recorded in FY2023.
  • Axsome Therapeutics' 5-year Change in Account Payables high stood at $31.3 million for FY2024, and its period low was -$355,000 during FY2021.
  • Its 3-year average for Change in Account Payables is $19.6 million, with a median of $25.5 million in 2022.
  • Its Change in Account Payables has fluctuated over the past 5 years, first tumbled by 113.86% in 2021, then skyrocketed by 7,270.70% in 2022.
  • Yearly analysis of 5 years shows Axsome Therapeutics' Change in Account Payables stood at $2.6 million in 2020, then plummeted by 113.86% to -$355,000 in 2021, then soared by 7,270.70% to $25.5 million in 2022, then slumped by 91.85% to $2.1 million in 2023, then spiked by 1,410.03% to $31.3 million in 2024.